Amylyx Pharmaceuticals FY 2022: revenue $22.2M; diluted EPS −$3.39

Key figures from this report

These are the numbers Amylyx Pharmaceuticals reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$22.2MNo year-earlier figure tagged10-K income statement, on EDGAR
2. Net income−$198.4MNo year-earlier figure tagged10-K income statement, on EDGAR
3. Diluted EPS−$3.39No year-earlier figure tagged10-K income statement, on EDGAR
4. Cash and cash equivalents$62.5MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations−$179.9MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables